

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Attorney Docket No. 2006_0367A
Yoshitaka TOMIGAHARA et al. : **Confirmation No. 5356**
Serial No. 10/572,705 : Group Art Unit 1626
Filed March 17, 2006 : Examiner Rebecca L. Anderson
CINNAMOYL DERIVATIVES AND USE : **Mail Stop: AMENDMENT**
THEREOF

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the information listed on attached Form PTO/SB/08.

1a. This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) the certification of paragraph 2 below is provided, or

The USPTO is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.492, which may be required by this paper to Deposit Account No. 23-0975.

(2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement (37 C.F.R. § 1.97(e)(1)), or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement (37 C.F.R. § 1.97(e)(2)).

3. For each non-English language reference listed on the attached Form PTO/SB/08, reference is made to one or more of the following:

- a. a full or partial English language translation submitted herewith,
- b. an International Search Report submitted herewith,
- c. a foreign patent office search report or office action (in the English language) submitted herewith,

- d. the concise explanation contained in the specification of the present application at page ,
- e. the concise explanation set forth in the attached English language abstract,
- f. the concise explanation set forth below or on a separate sheet attached to the reference:

4. A foreign patent office Office Action citing one or more references is enclosed.

5. Comments

The enclosed foreign patent office Office Action cites four Canadian publications, which correspond with four published U.S. patent applications, as follows:

CA 2539165 corresponds to US 2007/0265228, submitted with the Information Disclosure Statement (IDS) filed August 6, 2010;

CA 2538960 corresponds to US 2006/0211680, submitted with the IDS filed August 6, 2010;

CA 2600287 corresponds to US 2009/0143368, cited herein; and

CA 2611608 corresponds to US 2009/0275650, cited herein.

Respectfully submitted,

Yoshitaka TOMIGAHARA et al.

/Andrew B. Freistein/
By _____

Digitally signed by /Andrew B. Freistein/
DN: cn=/Andrew B. Freistein/, o=WLP,
ou=WLP, email=afreistein@wenderoth.
com, c=US
Date: 2011.08.01 14:58:44 -04'00'

Andrew B. Freistein
Registration No. 52,917
Attorney for Applicants

ABF/emj
Washington, D.C. 20005-1503
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 1, 2011